· QUICK SCAN

Risk Management & CAPA

Quality risk management as the engine of the PQS, and CAPA that actually prevents.

QMM · Advanced Pharmaceutical Quality SystemQMSQuality Management Systems
Assess this domain →
WHY IT MATTERS

Quality risk management (ICH Q9) is the engine of a modern pharmaceutical quality system, and CAPA is where a problem becomes prevention. A system that logs corrective actions but never verifies effectiveness — and keeps seeing the same deviation — is the textbook signature of a reactive operation. Maturity here is what turns single failures into system-wide immunity.

WHAT GOOD LOOKS LIKE

The observable evidence a practitioner — or an inspector — would expect at each maturity level. Drawn from the assessment questions themselves.

How are quality risks identified and managed across your operations?

1Foundational

Risks identified reactively after events occur

2Defined

Risk assessments performed for major changes only

3Managed

Proactive risk assessments using formal ICH Q9 methodology for processes and changes

4Quantified

Site-wide risk register with periodic review; risk metrics reported to quality council

5Optimized

Enterprise risk model with leading indicators and predictive analytics; risk posture continuously optimised and reviewed at board level

How does your CAPA system operate?

1Foundational

CAPAs logged but effectiveness rarely verified

2Defined

CAPAs have defined owners and due dates; effectiveness check is inconsistent

3Managed

Formal CAPA process with root cause analysis, implementation verification, and effectiveness check

4Quantified

CAPA system metrics trended and presented at management review; repeat deviations tracked

5Optimized

Self-improving CAPA system: predictive analytics pre-empt recurrence and feed prevention back into design and process controls

COMMON INSPECTION FINDINGS
  • CAPA effectiveness checks absent or perfunctory; repeat deviations recur for the same root cause.
  • Root-cause analysis stops at "operator error" and retraining without addressing the system that allowed it.
  • Risk assessments performed only for major changes, or scored subjectively without ICH Q9(R1) rigour.
  • CAPAs and investigations routinely exceed their own defined timelines.
RECOMMENDED SPEQ RESOURCES
TEMPLATEQuality Risk Assessment (QRA)STANDARDICH Q9(R1)
WHAT IT LOOKS LIKE WHEN IT FAILS — LIVE FDA RECALLS

Recent FDA recalls whose reason SPEQ maps to this domain — a SPEQ editorial interpretation of the recall reason, not an official FDA classification.

2026-07-22Class IAbiomed, Inc.

A potential for introducer sheath leakage from under the sheath cap and along the hub score lines, identified in 14Fr and 23Fr Introducers. These manufacturing issues are not visually detectable by the user, and 14Fr or 23Fr Introducers are provided in every pump set.

2026-07-22Class IAbiomed, Inc.

A potential for introducer sheath leakage from under the sheath cap and along the hub score lines, identified in 14Fr and 23Fr Introducers. These manufacturing issues are not visually detectable by the user, and 14Fr or 23Fr Introducers are provided in every pump set.

2026-07-22Class IAbiomed, Inc.

A potential for introducer sheath leakage from under the sheath cap and along the hub score lines, identified in 14Fr and 23Fr Introducers. These manufacturing issues are not visually detectable by the user, and 14Fr or 23Fr Introducers are provided in every pump set.

2026-07-22Class IAbiomed, Inc.

A potential for introducer sheath leakage from under the sheath cap and along the hub score lines, identified in 14Fr and 23Fr Introducers. These manufacturing issues are not visually detectable by the user, and 14Fr or 23Fr Introducers are provided in every pump set.

All recalls SPEQ maps to this domain →
ALL DOMAINS
Every maturity domain, decoded →
FDA QMM
How this rolls up to Advanced Pharmaceutical Quality System →
THE FRAMEWORK
Where this domain sits in the operating model →